NCIt definition : A humanized, immunoglobulin G1 monoclonal antibody with potential antitumor activity.
Farletuzumab specifically targets at glycoprotein 3 (GP-3), a cell surface antigen
that is overexpressed on many epithelial-derived cancer cells. Upon binding to the
GP-3 antigen, farletuzumab triggers a host immune response against GP-3 expressing
cells resulting in cell lysis.;
UNII : 2O09BG0OWA;
CAS number : 896723-44-7; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 896723-44-7
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;